Health Ministry Warns Against Counterfeit Coloverin-D Packages

The Libyan Health Ministry has issued a public warning on July 25, 2026, regarding the circulation of counterfeit Coloverin-D packages. The ministry advises patients and healthcare providers to avoid using these fraudulent versions of the medication to prevent potential health risks associated with substandard or falsified medical products, according to reporting from Libya Update.

The alert follows the discovery of packaging that mimics the authentic Coloverin-D brand. While the ministry has not detailed the specific chemical composition of the counterfeit units, the warning emphasizes the danger of using medication that does not originate from verified pharmaceutical channels.

Coloverin-D and the Risks of Counterfeit Medication

Coloverin-D is typically used to treat irritable bowel syndrome (IBS) and other gastrointestinal spasms. When medication is counterfeited, it may contain incorrect dosages of the active ingredient, no active ingredient at all, or harmful contaminants. According to the World Health Organization (WHO), substandard and falsified medical products threaten patient safety by causing treatment failure or increasing the risk of adverse reactions.

The Health Ministry’s intervention aims to stop the distribution of these packages before they reach a wider patient population. The ministry’s warning serves as a directive for pharmacies and clinics to verify the supply chain of their stock to ensure all Coloverin-D packages are legitimate.

Verification and Public Health Response

The Libyan Health Ministry has urged the public to report any suspicious packaging or unusual effects experienced after taking the medication. Public health officials recommend that patients only purchase medications from licensed pharmacies and avoid unofficial vendors or online sources that cannot provide proof of authenticity.

This warning is part of a broader effort by the ministry to regulate the pharmaceutical market and combat the entry of counterfeit drugs into the national healthcare system. The ministry continues to monitor the market for other potential falsified medicines that could jeopardize public health.